Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FluoAB intraoperative imaging for liver tumor
NCT05394246Unknown
- Sponsor
- Chinese Academy of Sciences
- Start
- May 2022
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies, Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Open-label, single-arm trial of FluoAB in liver cancer, sponsored by Chinese Academy of Sciences. Primary endpoints: Tumor imaging precision at 2 weeks and Tumor lesions. Status: unknown.
02
Drugs
FluoAB
03
Conditions
liver cancer
Beyond the preview
Go deeper on NCT05394246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05394246.